Naturally Occurring Bacterium from Japanese Tree Frog Intestines Demonstrates Potent Anticancer Activity in Preclinical Trials

In a significant advancement for the field of microbial oncology, researchers at the Japan Advanced Institute of Science and Technology (JAIST) have identified a specific bacterial strain derived from the intestines of the Japanese tree frog (Dryophytes japonicus) that possesses the ability to eliminate colorectal tumors in mice. The study, published in the peer-reviewed journal Gut Microbes, signals a paradigm shift in how scientists approach the relationship between bacteria and cancer. Rather than merely adjusting the gut microbiome to support overall health, this new methodology utilizes live, intravenously administered bacteria as a direct-action therapeutic agent.

The research team, led by Associate Professor Eijiro Miyako, discovered that the bacterium Ewingella americana—a naturally occurring microorganism—could achieve a 100% complete response rate in murine models of cancer. This discovery adds a new layer to the growing body of evidence suggesting that the natural world, particularly the unique microbiomes of diverse wildlife, may hold the key to overcoming treatment-resistant malignancies.

The Shift from Microbiome Modulation to Bacterial Therapy

For much of the last decade, cancer-related microbiome research has focused on the "gut-lung axis" or the "gut-brain axis," examining how the balance of bacteria in the digestive tract influences the body’s overall immune system. Treatments such as fecal microbiota transplants (FMT) and probiotic supplementation have been explored to enhance the efficacy of traditional immunotherapies. However, the JAIST study departs from this indirect approach.

By isolating individual strains and delivering them systemically via intravenous injection, the researchers transformed the bacteria into a "living drug." This approach allows the microorganisms to bypass the digestive tract and navigate the circulatory system to seek out and infiltrate solid tumors. The methodology relies on the inherent "tumor-homing" capabilities of certain bacteria, which are naturally drawn to the unique environment found within cancerous growths.

Chronology of the Discovery: From Field Collection to Laboratory Breakthrough

The journey toward this discovery began with an extensive survey of the biodiversity found in Japanese wetlands and forests. The research team collected 45 distinct bacterial strains from the intestines of three different species: the Japanese tree frog (Dryophytes japonicus), the Japanese fire belly newt (Cynops pyrrhogaster), and the Japanese grass lizard (Takydromus tachydromoides).

The research progressed through several critical phases:

1. Isolation and Cultivation: After collecting the samples, the researchers isolated the bacteria and grew them in controlled laboratory environments to create pure cultures.
2. Initial Screening: The 45 strains were screened for their ability to survive and proliferate in conditions mimicking the tumor microenvironment. From this group, nine strains were identified as having potential anticancer properties.
3. In Vitro Testing: The top candidates were tested against cancer cell lines to observe direct cytotoxic effects and immune-stimulating capabilities.
4. In Vivo Validation: The most promising strain, Ewingella americana, was then moved into animal models. Mice with induced colorectal cancer were given a single intravenous dose of the bacteria.
5. Comparative Analysis: The efficacy of E. americana was measured against the current gold standards of care, including immune checkpoint inhibitors (anti-PD-L1 antibodies) and high-potency chemotherapy (liposomal doxorubicin).

The results of the in vivo phase were startling: while standard therapies showed varying degrees of success in slowing tumor growth, E. americana achieved total tumor eradication in all treated subjects.

A Dual-Action Attack: Direct Proliferation and Immune Recruitment

The potency of Ewingella americana lies in its "dual-attack" mechanism, which targets the tumor through both biological and immunological pathways.

1. Direct Intratumoral Proliferation

E. americana is a facultative anaerobe, meaning it can survive in both oxygenated and oxygen-depleted environments. This is a critical characteristic for cancer therapy because solid tumors are notoriously hypoxic (low in oxygen) due to rapid, disorganized growth and poor blood vessel formation. While the low-oxygen environment of a tumor often acts as a shield against conventional chemotherapy and radiation, it serves as an ideal breeding ground for E. americana.

Within 24 hours of injection, the researchers observed a 3,000-fold increase in the bacterial population specifically within the tumor mass. This rapid colonization creates significant biological stress on the cancer cells, leading to direct tissue necrosis and the breakdown of the tumor’s structural integrity.

2. Orchestrating an Immune "Storm"

Beyond its direct physical impact, the presence of E. americana acts as a powerful flare for the host’s immune system. The bacteria trigger an acute inflammatory response within the tumor microenvironment, effectively "turning a cold tumor hot."

The researchers documented a massive influx of immune cells into the tumor site, including:

• T cells and B cells: The adaptive immune system’s primary hunters, which recognize and destroy abnormal cells.
• Neutrophils: The first responders of the innate immune system, which release enzymes to break down pathogens and damaged tissue.

These immune cells released high concentrations of signaling molecules known as cytokines, specifically Tumor Necrosis Factor-alpha (TNF-α) and Interferon-gamma (IFN-γ). This localized "cytokine storm" further accelerated the death of cancer cells and helped the immune system develop a "memory" of the malignancy, potentially preventing recurrence.

Safety Profiles and the Phenomenon of Tumor Tropism

One of the primary hurdles in developing bacterial therapies is the risk of systemic infection or sepsis. However, E. americana demonstrated a remarkable safety profile in the murine models. The researchers noted that the bacteria exhibited "tumor tropism"—a natural preference for cancerous tissue over healthy organs.

Several factors contribute to this specificity:

• Leaky Vasculature: Tumors have "leaky" blood vessels that allow larger particles, including bacteria, to exit the bloodstream and enter the tumor more easily than they would in healthy tissue.
• The EPR Effect: Known as the Enhanced Permeability and Retention effect, this phenomenon ensures that substances entering the tumor stay there longer due to poor lymphatic drainage.
• Immune Suppression within Tumors: Because tumors suppress the local immune response to protect themselves, they inadvertently create a "safe haven" for bacteria to multiply without being immediately cleared by the body.

Data from the study showed that E. americana was rapidly cleared from the general bloodstream, with a half-life of only 1.2 hours. Within 24 hours, the bacteria were virtually undetectable in the blood and healthy organs like the liver, spleen, and kidneys. The inflammation caused by the treatment was temporary, returning to baseline levels within 72 hours, and no chronic toxicity was observed over a 60-day monitoring period.

Historical Context: The Legacy of Coley’s Toxins

The use of bacteria to fight cancer is not a entirely new concept, though the JAIST study represents its most refined modern iteration. In the late 19th century, Dr. William Coley, a bone surgeon in New York, noticed that some cancer patients went into remission after developing post-operative skin infections. He began injecting patients with a mixture of killed bacteria (Streptococcus pyogenes and Serratia marcescens), which became known as "Coley’s Toxins."

While Coley saw significant success, the lack of standardized protocols and the rise of radiation therapy led to his methods falling out of favor. The JAIST research effectively bridges the gap between Coley’s early observations and modern genetic and microbiological precision, proving that the fundamental concept of using pathogens to stimulate an anticancer response remains valid.

Implications for Future Cancer Care

The implications of this study are far-reaching. If E. americana can be successfully transitioned into human clinical trials, it could offer a new line of defense for patients who have failed to respond to traditional chemotherapy or immunotherapy.

The JAIST team has outlined several next steps:

• Broadening the Scope: Testing the bacteria against other "hard-to-treat" solid tumors, such as pancreatic cancer, glioblastoma, and metastatic melanoma.
• Combination Therapies: Investigating whether E. americana can act as a "sensitizer," making tumors more vulnerable to existing chemotherapy drugs or PD-1/PD-L1 inhibitors.
• Optimization: Exploring "dose fractionation"—breaking the treatment into smaller, multiple doses—to maximize efficacy while further minimizing the risk of side effects.

The Value of Biodiversity in Medicine

This discovery also serves as a poignant reminder of the importance of ecological conservation. The bacteria responsible for this breakthrough were found in the gut of a common amphibian. As global biodiversity declines, the scientific community warns that we may be losing potential medical cures before they are even discovered.

The research was supported by several prestigious Japanese institutions, including the Japan Society for the Promotion of Science (JSPS) and the Japan Science and Technology Agency (JST). These organizations emphasize that exploring the "natural pharmacy" of the planet’s wildlife is a critical frontier in 21st-century medicine.

While the transition from mice to humans is a complex process with no guarantee of identical results, the 100% eradication rate observed in this study provides a powerful proof of concept. The "frog-derived" therapy stands as a testament to the potential of looking toward nature to solve the most complex challenges in human health.